School of Biological Sciences, Illinois State University, Normal, IL 61790-4120, USA.
BMC Cancer. 2011 Aug 10;11:347. doi: 10.1186/1471-2407-11-347.
Activation Induced cytidine Deaminase (AID) targets the immunoglobulin genes of activated B cells, where it converts cytidine to uracil to induce mutagenesis and recombination. While essential for immunoglobulin gene diversification, AID misregulation can result in genomic instability and oncogenic transformation. This is classically illustrated in Burkitt's lymphoma, which is characterized by AID-induced mutation and reciprocal translocation of the c-MYC oncogene with the IgH loci. Originally thought to be B cell-specific, AID now appears to be misexpressed in several epithelial cancers, raising the specter that AID may also participate in non-B cell carcinogenesis.
The mutagenic potential of AID argues for the existence of cellular regulators capable of repressing inappropriate AID expression. MicroRNAs (miRs) have this capacity, and we have examined the publically available human AID EST dataset for miR complementarities to the human AID 3'UTR. In this work, we have evaluated the capacity of two candidate miRs to repress human AID expression in MCF-7 breast carcinoma cells.
We have discovered moderate miR-155 and pronounced miR-93 complementary target sites encoded within the human AID mRNA. Luciferase reporter assays indicate that both miR-93 and miR-155 can interact with the 3'UTR of AID to block expression. In addition, over-expression of either miR in MCF-7 cells reduces endogenous AID protein, but not mRNA, levels. Similarly indicative of AID translational regulation, depletion of either miR in MCF-7 cells increases AID protein levels without concurrent increases in AID mRNA.
Together, our findings demonstrate that miR-93 and miR-155 constitutively suppress AID translation in MCF-7 cells, suggesting widespread roles for these miRs in preventing genome cytidine deaminations, mutagenesis, and oncogenic transformation. In addition, our characterization of an obscured miR-93 target site located within the AID 3'UTR supports the recent suggestion that many miR regulations have been overlooked due to the prevalence of truncated 3'UTR annotations.
激活诱导胞嘧啶脱氨酶(AID)靶向激活 B 细胞的免疫球蛋白基因,在那里它将胞嘧啶转化为尿嘧啶以诱导突变和重组。虽然 AID 对于免疫球蛋白基因多样化至关重要,但 AID 的失调可能导致基因组不稳定和致癌转化。这在伯基特淋巴瘤中得到了经典的说明,伯基特淋巴瘤的特征是 AID 诱导的突变和 c-MYC 癌基因与 IgH 基因座的相互易位。最初认为 AID 是 B 细胞特异性的,但现在似乎在几种上皮癌中表达错误,这让人担心 AID 也可能参与非 B 细胞癌的发生。
AID 的诱变潜力表明存在能够抑制不适当 AID 表达的细胞调节剂。微小 RNA(miRs)具有这种能力,我们已经检查了公开的人类 AID EST 数据集,以寻找与人类 AID 3'UTR 互补的 miR。在这项工作中,我们评估了两种候选 miR 抑制 MCF-7 乳腺癌细胞中人类 AID 表达的能力。
我们发现人类 AID mRNA 内编码的 miR-155 中度互补和 miR-93 显著互补靶位点。荧光素酶报告基因测定表明,miR-93 和 miR-155 都可以与 AID 的 3'UTR 相互作用以阻断表达。此外,在 MCF-7 细胞中过表达任一种 miR 都会降低内源性 AID 蛋白,但不降低 AID mRNA 水平。同样表明 AID 翻译调控,在 MCF-7 细胞中耗尽任一种 miR 会增加 AID 蛋白水平,而不会同时增加 AID mRNA 水平。
总之,我们的发现表明 miR-93 和 miR-155 在 MCF-7 细胞中持续抑制 AID 翻译,表明这些 miR 在防止基因组胞嘧啶脱氨酶、突变和致癌转化方面具有广泛的作用。此外,我们对 AID 3'UTR 内一个被掩盖的 miR-93 靶位点的特征描述支持了最近的一个观点,即由于截断的 3'UTR 注释的普遍性,许多 miR 调控作用被忽视了。